Anti‐IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

Scolaris Content Display Scolaris Content Display

Ir a:

Figure 1

Study flow diagram.

Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Table 1. Adverse effects in included trial

AEs	Omalizumab group N = 9, n (%)	Placebo group N = 5, n (%)
Non‐serious AEs
Participants with AE(s)	9 (100)	5 (100)
Infective pulmonary exacerbation of CF	7 (78)	4 (80)
Cough	4 (44)	1 (20)
Headache	4 (44)	1 (20)
Pyrexia	3 (33)	2 (40)
Hemoptysis (blood in sputum)	4 (44)	0
Injection site swelling	4 (44)	0
Injection site warmth	4 (44)	0
Injection site erythema (redness)	3 (33)	0
Hypokalemia	2 (22)	0
Nasopharyngitis	2 (22)	0
Sputum increased	1 (11)	1 (20)
Bronchopulmonary aspergillosis allergic	2 (22)	0
Rhonchi (noisy expiratory breathing sound)	1 (11)	1 (20)
Non‐cardiac chest pain	1 (11)	1 (20)
Vomiting	0	1 (20)
SAEs
Participants with any SAE	6 (67)	1 (20)
Infective pulmonary exacerbation of CF	5 (56)	1 (20)
Allergic Bronchopulmonary Aspergillosis	2 (22)	0
Distal intestinal obstruction syndrome	1 (11)	0
Hemoptysis	1 (11)	0
Rhonchi	1 (11)	0
AE: adverse event CF: cystic fibrosis SAE: serious adverse event

Table 1. Adverse effects in included trial